Download PDF
Semin Thromb Hemost 2001; 27(2): 099-106
DOI: 10.1055/s-2001-14067
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Activated Protein C Prevents Development of Phosphatidylserine-Induced Intrauterine Growth Restriction in Mice

Fang Shu, Motoi Sugimura, Hiroshi Kobayashi, Takao Kobayashi, Naohiro Kanayama
  • Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

We examined the effect of activated protein C (APC) on the development of intrauterine growth restriction (IUGR) in an experimental animal model we established. The IUGR in mice was induced by artificial phosphatidylserine (PS)/phosphatidylcholine (PC) microvesicles that represent procoagulant phospholipids derived from activated platelets. This model represents the placental insufficiency associated with the phospholipid-induced hypercoagulable state in placental circulation. APC prolonged the activated partial thromboplastin time (aPTT) using mouse plasma and dose dependently inhibited thrombin generation in a chromogenic assay in defibrinated plasma of mice. Administration of exogenous APC at concentrations that maximally inhibited thrombin generation in defibrinated plasma prevented a significant reduction in fetal body weight and induced marked histological changes including congestion and fibrin depositions in IUGR mouse placentas. These results suggest that the inhibition of thrombin generation in the placental circulation by APC prevents the development of IUGR that is dependent on coagulation associated with PS/PC from activated platelets.

KEYWORD

Activated protein C (APC) - intrauterine growth restriction (IUGR) - thrombin - phosphatidylserine

REFERENCES

  • 1 Vandenbosche R C, Kirchner J T. Intrauterine growth retardation.  Am Fam Physician. 1998;  58 1384-1390-1393-1394
    PubMedGoogle Scholar
  • 2 Lockwood C J, Rand J H. The immunobiology and obstetrical consequences of anti-phospholipid antibodies.  Obstet Gynecol Surv . 1994;  49 432-441
    CrossrefPubMedGoogle Scholar
  • 3 Sugimura M, Shu F, Kanayama N, Kobayashi H, Kobayashi T, Terao T. Anticoagulant activity in non-immunoglobulin fraction from plasma of patients with antiphospholipid syndrome.  Semin Thromb Hemost . 1998;  24 473-477
    PubMedGoogle Scholar
  • 4 Stenflo J, Fernlund P, Roepstorff P. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization.  J Biol Chem . 1976;  251 355-363
    PubMedGoogle Scholar
  • 5 Esmon C T, Stenflo J, Suttie J W. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase.  J Biol Chem . 1976;  251 3052-3056
    PubMedGoogle Scholar
  • 6 Kisiel W, Canfield W M, Ericsson L H, Davie E W. Anticoagulant properties of bovine plasma protein C following activation by thrombin.  Biochemistry . 1977;  16 5824-5831
    CrossrefPubMedGoogle Scholar
  • 7 Walker F J, Sexton P W, Esmon C T. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V.  Biochim Biophys Acta . 1979;  571 333-342
    PubMedGoogle Scholar
  • 8 Comp P C, Esmon C T. Activated protein C inhibits platelet prothrombin-converting activity.  Blood . 1979;  54 1272-1281
    PubMedGoogle Scholar
  • 9 Dahlbäck B, Stenflo J. Inhibitory effect of activated protein C on activation of prothrombin by platelet-bound factor Xa.  Eur J Biochem . 1980;  107 331-335
    PubMedGoogle Scholar
  • 10 Gresele P, Momi S, Berrettini M. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.  J Clin Invest . 1998;  101 667-676
    CrossrefPubMedGoogle Scholar
  • 11 Sakamoto T, Ogawa H, Yasue H. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.  Circulation . 1994;  90 427-432
    PubMedGoogle Scholar
  • 12 Yamashita T, Tsuda Y, Konishi Y. The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.  Thromb Res . 1994;  90 199-206
    PubMedGoogle Scholar
  • 13 Vileisis R A. Effect of maternal oxygen inhalation on the fetus with growth retardation.  Pediatr Res . 1985;  19 324-327
    PubMedGoogle Scholar
  • 14 Unterman T, Lascon R, Gotway M B. Circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) and hepatic mRNA are increased in the small for gestational age (SGA) fetal rat.  Endocrinology . 1990;  127 2035-2037
    PubMedGoogle Scholar
  • 15 Straus D S, Ooi G T, Orlowski C C, Rechler M M. Expression of the genes for insulin-like growth factor-I (IGF-I), IGF-II, and IGF-binding proteins-1 and -2 in fetal rat under conditions of intrauterine growth retardation caused by maternal fasting.  Endocrinology . 1991;  128 518-525
    PubMedGoogle Scholar
  • 16 Bernstein I M, DeSouza M M, Copeland K C. Insulin-like growth factor I in substrate-deprived, growth-retarded fetal rats.  Pediatr Res . 1991;  30 154-157
    PubMedGoogle Scholar
  • 17 Price W A, Stiles A D, Moats-Staats B M, D'Ercole A J. Gene expression of insulin-like growth factors (IGFs), the type 1 IGF receptor, and IGF-binding proteins in dexamethasone-induced fetal growth retardation.  Endocrinology . 1992;  130 1424-1432
    CrossrefPubMedGoogle Scholar
  • 18 Block B S, Schlafer D H, Wentworth R A, Kreitzer L A, Nathanielsz P W. Regional blood flow distribution in fetal sheep with intrauterine growth retardation produced by decreased umbilical placental perfusion.  J Dev Physiol . 1990;  13 81-85
    PubMedGoogle Scholar
  • 19 Sugimura M, Kobayashi T, Shu F, Kanayama N, Terao T. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice.  Placenta . 1999;  20 555-560
    CrossrefPubMedGoogle Scholar
  • 20 Nicolaes G A, Thomassen M C, Tans G, Rosing J, Hemker H C. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals.  Blood Coagul Fibrinolysis . 1997;  8 28-38
    PubMedGoogle Scholar
  • 21 Hemker H C, Willems G M, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes.  Thromb Haemost . 1986;  56 9-17
    PubMedGoogle Scholar
  • 22 Mallory F B. A contribution to staining methods. III. Phosphotungstic acid-hematoxylin for neuroglia fibers.  J Exp Med . 1900;  5 19-20
    PubMedGoogle Scholar
  • 23 Puchtler H, Sweat F, Doss N O. A one-hour phosphotungstic acid-hematoxylin stain.  Am J Clin Pathol . 1963;  40 334-337
    PubMedGoogle Scholar
  • 24 Beguin S, Lindhout T, Hemker H C. The mode of action of heparin in plasma.  Thromb Haemost . 1988;  60 457-462
    PubMedGoogle Scholar
  • 25 Wielders S, Mukherjee M, Michiels J. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability.  Thromb Haemost . 1997;  77 629-636
    PubMedGoogle Scholar
  • 26 Fukudome K, Esmon C T. Identification, cloning, and regulation of a novel endothelial cell protein C activated protein C receptor.  J Biol Chem . 1994;  269 26486-26491
    PubMedGoogle Scholar